Table 1.
Studies, Intervention, and Patients Characteristics and Risk of Bias of Included RPCCTs
| Studies | |
|---|---|
| Number of studies | 43 |
| Number of drug-placebo comparisons | 60 |
| Number of patients/study (median) | 268 |
| Multi-site studies (%) | 88.1 |
| Lead-in period (%) | 25.6 |
| Placebo lead-in period (%) | 90.9 |
| Interventiona | |
| Donepezil (%) | 45.0 |
| Galantamine (%) | 26.7 |
| Rivastigmine (%) | 28.3 |
| Dose (%)b | |
| Low | 27.3 |
| High | 72.7 |
| Dosage (%) | |
| Fixed | 60.0 |
| Flexible | 40.0 |
| Length (mean) | 25.1 |
| 12–24 weeks (%) | 23.3 |
| ≥24–36 weeks (%) | 68.4 |
| ≥36 weeks (%) | 8.3 |
| Patients | |
| Number of patients | 16,106 |
| Age (years) | 74.5 |
| Women (%) | 63.4 |
| Cognitive function (mean)c | 57.7 |
| Neuropsychiatric symptom severity (mean)c | 13.5 |
| Functionality (mean)c | 62.2 |
| High risk of biasd | |
| Discontinuation outcomes | 0 |
| Efficacy cognitive function | 22.0 |
| Efficacy global change | 25.0 |
| Efficacy neuropsychiatric symptoms | 21.1 |
| Efficacy functional capacity | 33.3 |
| Mortality | 17.3 |
| Any AE | 23.5 |
| SAE | 16.7 |
Abbreviations: AE, adverse event; SAE, serious adverse event.
aProportion of drug-placebo comparisons.
bHigh, mean daily dose of donepezil >7.5 mg, galantamine >16 mg, and rivastigmine >5.5 mg; Low, mean daily dose of donepezil <7.5 mg; galantamine <16 mg, and rivastigmine <5.5 mg.
cAs a percentage of scale maxima (0–100).
dProportion of comparisons with high risk of bias for each outcome.